CG Oncology Q2 2026 Results and Milestones

CG Oncology, Inc. reported its second quarter 2026 financial results and provided business updates. The company highlighted progress in its clinical pipeline, including the anticipation of Phase 3 topline data from the PIVOT-006 trial in intermediate-risk NMIBC and the expected completion of a Biologics License Application (BLA) submission for high-risk BCG-unresponsive NMIBC in the fourth quarter of 2026. In July, results from the BOND-003 Cohort C study were published in The Lancet, validating the clinical evidence for cretostimogene. Additionally, the United States — Superior Court of the State of Delaware denied ANI Pharmaceuticals' post-trial motion, upholding a jury verdict in favor of CG Oncology regarding a severed royalty provision. Financially, CG Oncology reported a net loss of $79.1 million for the quarter, with cash and marketable securities of approximately $1.0 billion, sufficient to fund operations through 2029.